piribedil has been researched along with Parkinson Disease in 90 studies
Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "No studies have previously reported the simultaneous observation of position-unrelated hypotension and bradycardia after taking small doses of piribedil." | 8.98 | Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review. ( Li, Y; Nie, K; Wang, L; Zhang, P; Zhang, Y, 2018) |
| "Case reports of six parkinsonian patients on piribedil presenting pathological gambling (PG)." | 7.81 | Piribedil and pathological gambling in six parkinsonian patients. ( Calvo, DS; Espinosa, ME; Giugni, JC; Micheli, FE; Raina, GB, 2015) |
| "Piribedil was one of the first agonists to be marketed (1969) and is widely used as an extended-release oral formulation in European, Latin-American, and Asian countries." | 6.53 | Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. ( Perez-Lloret, S; Rascol, O, 2016) |
| "Several controlled trials have shown that the dopamine agonist, Trivastal (piribedil), is active in the treatment of Parkinson's disease, particularly with regard to tremor." | 5.07 | Activity and acceptability of piribedil in Parkinson's disease: a multicentre study. ( Rondot, P; Ziegler, M, 1992) |
| "A double-blind, cross-over trial of the effectiveness of piribedil, procyclidine and placebo in the control of parkinsonism induced by fluphenazine decanoate was conducted in sixteen cases of chronic schizophrenia." | 5.04 | A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism. ( Bradley, R; Lamb, P; Mindham, RH, 1977) |
| "No studies have previously reported the simultaneous observation of position-unrelated hypotension and bradycardia after taking small doses of piribedil." | 4.98 | Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review. ( Li, Y; Nie, K; Wang, L; Zhang, P; Zhang, Y, 2018) |
| "The inclusion of piribedil (150-250 mg/day) in the 6-months therapy reduces the dysfunction of the upper gastrointestinal tract (by 61 and 74% of the initial level of dysphagia and sialorrhea, respectively) regardless the drug use in monotherapy or in complex therapy with levodopa." | 4.12 | [Upper gastrointestinal tract dysfunction and its correction by dopamine agonists for patients with Parkinson's disease of I-III stage]. ( Pilipovich, AA; Vorob'eva, OV, 2022) |
| "Case reports of six parkinsonian patients on piribedil presenting pathological gambling (PG)." | 3.81 | Piribedil and pathological gambling in six parkinsonian patients. ( Calvo, DS; Espinosa, ME; Giugni, JC; Micheli, FE; Raina, GB, 2015) |
| " The aims of this study were therefore (1) to investigate the anti-dyskinetic effects of piribedil on L-DOPA-induced contralateral turning behaviour, locomotive dyskinesias (LD), axial dystonia (AD), orolingual dyskinesia (OD) and forelimb dyskinesia (FD) and (2) to compare these effects to the α(2) adrenoceptor antagonist, idazoxan, or the α(2) adrenoceptor agonist, clonidine." | 3.79 | The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. ( Gerlach, M; Halley, P; Riederer, P; van den Buuse, M, 2013) |
| "The Unified Parkinson's Disease Rating Scale scores, TCM symptoms scores, quality of life, change of Madopar's dosage and the toxic and adverse effects of Madopar will be observed during a 3-month treatment period and through a further 6-month follow-up period." | 2.78 | Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial. ( Ma, YZ; Shen, XM; Zhang, J, 2013) |
| "Dopamine agonists have been recommended as early treatment for Parkinson's disease (PD), alone or combined with levodopa." | 2.72 | The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. ( Aguilar, M; Castro-Caldas, A; Cesaro, P; Del Signore, S; Delwaide, P; Jost, W; Lamberti, P; Merello, M; Williams, A, 2006) |
| "Piribedil is a D2 dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L-dopa." | 2.72 | Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. ( Caldas, AC; Del Signore, S; Dubois, B; Lees, A; Rascol, O; Senn, S, 2006) |
| "Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2-16 mg) and placebo." | 2.71 | End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study. ( Alicherif, A; Azulay, JP; Blin, O; Lesourd, M; Micallef, J; Reynier, JC; Simon, N; Witjas, T, 2005) |
| "Sixty patients with different types of Parkinson's disease (PD), the disease stage 2." | 2.71 | [An impact of pronoran on cognitive and affective disorders in Parkinson's disease]. ( Golubev, VL; Pilipovich, AA, 2005) |
| "Piribedil was effective on motor symptoms during a 6-month treatment in early parkinsonian patients insufficiently controlled by L-dopa and it was well tolerated." | 2.71 | Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study. ( Bundhukul, A; Chankrachang, S; Laptikultham, S; Nidhinandana, S; Pisarnpong, A; Srisuwananukorn, S; Suwantamee, J, 2004) |
| "Efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) III score as primary criterion over 4 months." | 2.71 | Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. ( Castro-Caldas, A; Del Signore, S; Rascol, O; Ziegler, M, 2003) |
| " Pronoran ("Servier", France) combined with levodopa was used in dosage 50-150 mg daily during 6 months." | 2.71 | [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study]. ( Fedorova, NV, 2003) |
| "Twenty-seven patients with idiopathic Parkinson's disease, treated with L-dopa but not sufficiently controlled, were included in this trial." | 2.69 | A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease. ( Malbezin, M; Montastruc, JL; Rascol, O; Ziegler, M, 1999) |
| "The further therapeutic benefit of piribedil when combined with amantadine or Levodopa was studied by a double-blind, cross-over trial in 15 patients with Parkinson's disease." | 2.64 | Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa. ( Callaghan, N; Fitzpatrick, E; O'Mahony, JB, 1975) |
| "Piribedil was one of the first agonists to be marketed (1969) and is widely used as an extended-release oral formulation in European, Latin-American, and Asian countries." | 2.53 | Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. ( Perez-Lloret, S; Rascol, O, 2016) |
| "Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias." | 2.43 | Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. ( Goetz, CG; Poewe, W; Rascol, O; Sampaio, C, 2005) |
| "Apomorphine is a non-ergot derivative dopamine agonist, which is used subcutaneously for the treatment of severe 'off' refractory periods, in combination with other dopaminergic drugs without changing the patient's routine drug regimen." | 2.38 | Current status of dopamine agonists in Parkinson's disease management. ( Montastruc, JL; Rascol, O; Senard, JM, 1993) |
| "In patients with Parkinson's disease the beneficial effects of piribedil may be limited by nausea and drowsiness." | 2.38 | Parkinson's disease: pathological mechanisms and actions of piribedil. ( Jenner, P, 1992) |
| "With the exception of Parkinson's disease, there is little evidence that treatments which decrease DA function are potent inducers of depression, but it is argued that such a relationship might not necessarily be expected." | 2.36 | Dopamine and depression: a review of recent evidence. I. Empirical studies. ( Willner, P, 1983) |
| "Piribedil (PBD) is a compound that has shown efficacy in clinical trials to treat motor and non-motor symptoms of Parkinson's disease." | 1.62 | Design and evaluation of thermo-responsive nasal in situ gelling system dispersed with piribedil loaded lecithin-chitosan hybrid nanoparticles for improved brain availability. ( Dalvi, AV; Ravi, PR; Uppuluri, CT, 2021) |
| " But its clinical use is severely limited by drug delivery issues like high dosing frequency (up to 5 tablets/day), low oral bioavailability (<10%), severe GI side-effects, etc." | 1.62 | Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson's disease. ( Dalvi, AV; Ravi, PR; Uppuluri, CT, 2021) |
| "The aim of this study was optimization of buccal piribedil (PR) mucoadhesive tablets to improve its low bioavailability and provide controlled release for the treatment of Parkinson's disease." | 1.46 | Optimization of piribedil mucoadhesive tablets for efficient therapy of Parkinson's disease: physical characterization and ex vivo drug permeation through buccal mucosa. ( Barla Demirkoz, A; Çelik, B; Özdemir, S; Üner, M, 2017) |
| "Piribedil is a dopamine agonist used in Parkinson's disease and a variety of other clinical situations although its efficacy has not been demonstrated." | 1.39 | Piribedil: sleep attacks, also in patients without Parkinson's disease. ( , 2013) |
| "Three patients with Parkinson's disease had so-called sleep attacks at the wheel while taking bromocryptine, lisuride pergolide, or piribedil." | 1.31 | Sleep attacks and Parkinson's disease treatment. ( Ferreira, JJ; Galitzky, M; Montastruc, JL; Rascol, O, 2000) |
| "Fifteen patients with idiopathic Parkinson's disease and 15 controls were tested with a span paradigm to assess the effects reflecting the functioning of the phonological loop: the phonological similarity effect (in verbal and visual presentation), and the word length effect (in visual presentation)." | 1.30 | The phonological loop in medicated patients with Parkinson's disease: presence of phonological similarity and word length effects. ( Fournet, N; Moreaud, O; Naegele, B; Pellat, J; Roulin, JL, 1997) |
| "Certain clinical manifestations of Parkinson's disease (PD) (speech or/and balance disturbances) are not linked to brain dopamine deficiency." | 1.28 | Cardiac beta-adrenoceptor sensitivity and Parkinson's disease. ( Allain, H; Bentue-Ferrer, D; Decombe, R; Lemaitre, MH; Martinet, JP; Milon, D, 1991) |
| "Sixty cases of Parkinson's disease were treated with piribedil alone (dose : 274 mg/day, duration : 20,4 months)." | 1.26 | [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)]. ( Bastard, J; Chanelet, J; Emile, J; Six, P; Truelle, JL, 1977) |
| " Two lines of evidence strongly suggest that the bursting pallidal activities are a consequence of the interruption of the nigrostriatal dopaminergic pathway: (1) the percentage of bursting pallidal neurons is proportional to the amount of degeneration in the pars compacta of the ipsilateral substantia nigra; (2) chronic administration of dopamine antagonists, haloperidol and reserpine, reproduces in intact monkeys the bursting activities observed in lesioned animals." | 1.26 | Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey. ( Filion, M, 1979) |
| " Twelve of the 13 clearly benefited from the addition of Piribedil although side effects precluded long term use in two cases." | 1.26 | Piribedil: its synergistic effect in multidrug regimens for parkinsonism. ( Feigenson, JS; McDowell, FH; Sweet, RD, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (42.22) | 18.7374 |
| 1990's | 7 (7.78) | 18.2507 |
| 2000's | 25 (27.78) | 29.6817 |
| 2010's | 14 (15.56) | 24.3611 |
| 2020's | 6 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Uppuluri, CT | 2 |
| Ravi, PR | 2 |
| Dalvi, AV | 2 |
| Pilipovich, AA | 6 |
| Vorob'eva, OV | 4 |
| Pokhabov, DV | 1 |
| Tunik, ME | 1 |
| Pokhabov, DD | 1 |
| Katunina, EA | 1 |
| Zalyalova, ZA | 1 |
| Zhang, R | 1 |
| Li, J | 1 |
| Wu, Y | 1 |
| Liang, S | 1 |
| Xu, L | 1 |
| Çelik, B | 1 |
| Özdemir, S | 1 |
| Barla Demirkoz, A | 1 |
| Üner, M | 1 |
| Zhang, P | 1 |
| Li, Y | 1 |
| Nie, K | 1 |
| Wang, L | 1 |
| Zhang, Y | 1 |
| Thobois, S | 1 |
| Lhommée, E | 1 |
| Klinger, H | 1 |
| Ardouin, C | 1 |
| Schmitt, E | 1 |
| Bichon, A | 1 |
| Kistner, A | 1 |
| Castrioto, A | 1 |
| Xie, J | 1 |
| Fraix, V | 1 |
| Pelissier, P | 1 |
| Chabardes, S | 1 |
| Mertens, P | 1 |
| Quesada, JL | 1 |
| Bosson, JL | 1 |
| Pollak, P | 2 |
| Broussolle, E | 1 |
| Krack, P | 1 |
| Zhang, J | 1 |
| Ma, YZ | 1 |
| Shen, XM | 1 |
| Micheli, FE | 1 |
| Giugni, JC | 1 |
| Espinosa, ME | 1 |
| Calvo, DS | 1 |
| Raina, GB | 1 |
| Song, JH | 1 |
| Zhou, PY | 1 |
| Cao, ZH | 1 |
| Ding, ZG | 1 |
| Chen, HX | 1 |
| Zhang, GB | 1 |
| Fedorova, NV | 3 |
| Kulua, TK | 1 |
| Gubanova, ЕN | 1 |
| Perez-Lloret, S | 1 |
| Rascol, O | 8 |
| Mil'chakova, AE | 1 |
| Popov, GR | 1 |
| Bykov, AV | 1 |
| Gekht, AB | 4 |
| Azulay, JP | 2 |
| Blin, O | 2 |
| Bonnet, AM | 3 |
| Brefel-Courbon, C | 1 |
| Césaro, P | 2 |
| Damier, P | 1 |
| Debilly, B | 1 |
| Durif, F | 1 |
| Galitzky, M | 2 |
| Grouin, JM | 1 |
| Pennaforte, S | 1 |
| Villafane, G | 1 |
| Yaici, S | 1 |
| Agid, Y | 3 |
| Millan, MJ | 1 |
| Kölle, M | 1 |
| Lepping, P | 1 |
| Kassubek, J | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Freudenmann, RW | 1 |
| Marusiak, J | 1 |
| Jaskólska, A | 1 |
| Koszewicz, M | 1 |
| Budrewicz, S | 1 |
| Jaskólski, A | 1 |
| Gerlach, M | 1 |
| Halley, P | 1 |
| Riederer, P | 1 |
| van den Buuse, M | 1 |
| Tan, EK | 3 |
| Ratnagopal, P | 1 |
| Han, SY | 1 |
| Wong, MC | 1 |
| Ziegler, M | 5 |
| Castro-Caldas, A | 2 |
| Del Signore, S | 3 |
| Artem'eva, EG | 1 |
| Gigir', IP | 1 |
| Levin, OS | 1 |
| Evidente, VG | 1 |
| Esteban, RP | 1 |
| Domingo, FM | 1 |
| Carbajal, LO | 1 |
| Parazo, MA | 1 |
| Karpova, EA | 1 |
| Ivanova-Smolenskaia, IA | 1 |
| Chernikova, LA | 1 |
| Markova, ED | 1 |
| Illarioshkin, SN | 1 |
| Simon, N | 1 |
| Micallef, J | 1 |
| Reynier, JC | 1 |
| Lesourd, M | 1 |
| Witjas, T | 1 |
| Alicherif, A | 1 |
| Goetz, CG | 1 |
| Poewe, W | 1 |
| Sampaio, C | 1 |
| Suwantamee, J | 1 |
| Nidhinandana, S | 1 |
| Srisuwananukorn, S | 1 |
| Laptikultham, S | 1 |
| Pisarnpong, A | 1 |
| Chankrachang, S | 1 |
| Bundhukul, A | 1 |
| Golubev, VL | 2 |
| Delwaide, P | 1 |
| Jost, W | 1 |
| Merello, M | 1 |
| Williams, A | 1 |
| Lamberti, P | 1 |
| Aguilar, M | 1 |
| Artem'ev, DV | 1 |
| Turle-Lorenzo, N | 1 |
| Maurin, B | 1 |
| Puma, C | 1 |
| Chezaubernard, C | 1 |
| Morain, P | 1 |
| Baunez, C | 1 |
| Nieoullon, A | 1 |
| Amalric, M | 1 |
| Dubois, B | 2 |
| Caldas, AC | 1 |
| Senn, S | 1 |
| Lees, A | 1 |
| Burton, K | 1 |
| Calne, DB | 1 |
| Bathien, N | 2 |
| Rondot, P | 4 |
| Koutlidis, RM | 1 |
| Willner, P | 1 |
| Kurako, IuL | 1 |
| Volianskiĭ, VE | 1 |
| Meltzer, HY | 1 |
| Dourish, CT | 1 |
| Georgiadis, G | 1 |
| Elghozi, JL | 1 |
| Montastruc, JL | 3 |
| Senard, JM | 1 |
| Moreaud, O | 1 |
| Fournet, N | 1 |
| Roulin, JL | 1 |
| Naegele, B | 1 |
| Pellat, J | 1 |
| Malbezin, M | 1 |
| Ferreira, JJ | 1 |
| Casacchia, M | 1 |
| Carolei, A | 1 |
| Zamponi, A | 1 |
| Agnoli, A | 1 |
| Fazio, C | 1 |
| Truelle, JL | 4 |
| Chanelet, J | 4 |
| Bastard, J | 4 |
| Six, P | 2 |
| Emile, J | 4 |
| Hungerbühler, JP | 1 |
| Regli, F | 1 |
| Parkes, JD | 1 |
| Filion, M | 1 |
| Lieberman, AN | 1 |
| Shopsin, B | 1 |
| Brun, YL | 1 |
| Boal, D | 1 |
| Zolfaghari, M | 1 |
| Shoulson, I | 3 |
| Chase, T | 1 |
| Iversen, LL | 1 |
| Horn, AS | 1 |
| Miller, RJ | 1 |
| Engel, J | 1 |
| Granerus, AK | 1 |
| Svanborg, A | 1 |
| Schmitt, H | 1 |
| Laubie, M | 1 |
| Poignant, JC | 1 |
| Krikorian, A | 1 |
| Evrard, Y | 1 |
| Freyria, JL | 1 |
| Arnaud, F | 1 |
| Oules, MJ | 1 |
| Boscredon, J | 1 |
| Mindham, RH | 1 |
| Lamb, P | 1 |
| Bradley, R | 1 |
| Barroche, G | 1 |
| Javoy-Agid, F | 1 |
| Kato, G | 1 |
| Lhermitte, F | 1 |
| Signoret, JL | 1 |
| Ohmoto, T | 1 |
| Miyamoto, T | 1 |
| Baba, Y | 1 |
| Chase, TN | 2 |
| Barbeau, A | 1 |
| Rinne, UK | 3 |
| Marttila, R | 3 |
| Sonninen, V | 3 |
| Feigenson, JS | 1 |
| Sweet, RD | 2 |
| McDowell, FH | 3 |
| Sweet, R | 1 |
| Dumas, JL | 1 |
| Callaghan, N | 1 |
| Fitzpatrick, E | 1 |
| O'Mahony, JB | 1 |
| Jenner, P | 1 |
| Milon, D | 1 |
| Allain, H | 1 |
| Bentue-Ferrer, D | 1 |
| Martinet, JP | 1 |
| Lemaitre, MH | 1 |
| Decombe, R | 1 |
| Mentenopoulos, G | 1 |
| Katsarou, Z | 1 |
| Bostantjopoulou, S | 1 |
| Logothetis, J | 1 |
| Kapfhammer, HP | 1 |
| Rüther, E | 1 |
| Wasterlain, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Myofascial Trigger Points Therapy in Migraine.[NCT05646160] | 100 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | |||
| Stabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.[NCT00725478] | 250 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.[NCT00727727] | 750 participants (Anticipated) | Observational | 2008-03-31 | Completed | |||
| Efficacy and Safety of Long-term Therapy With Piribedil (CLARIUM) in Patients With M. Parkinson Under Consideration of Quality of Life Parameters and Cognitive Function[NCT01519856] | 908 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for piribedil and Parkinson Disease
| Article | Year |
|---|---|
[Postural stability and walking in Parkinson's disease].
Topics: Dopamine Agonists; Humans; Parkinson Disease; Piribedil; Postural Balance; Walking | 2023 |
Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review.
Topics: Bradycardia; Dopamine; Dopamine Agonists; Humans; Hypotension; Male; Middle Aged; Parkinson Disease; | 2018 |
Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Double-Blind Method; Evidence-Based Medicine; Huma | 2016 |
[Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
Topics: Antiparkinson Agents; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Parkinson Disease; | 2008 |
From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Dopamine Agonists; Drug Partial Agonism; Humans; P | 2010 |
[Alpha-2 adrenergic receptors and Parkinson's disease].
Topics: Adrenergic alpha-2 Receptor Antagonists; Antiparkinson Agents; Humans; Levodopa; Neuroprotective Age | 2002 |
DA agonists -- non-ergot derivatives: piribedil: management of Parkinson's disease.
Topics: Dopamine Agonists; Humans; Parkinson Disease; Piribedil; Randomized Controlled Trials as Topic | 2002 |
[Use of dopamine agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topi | 2002 |
[Use of dopamine analogs in Parkinson's disease treatment].
Topics: Dopamine; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Piribedil; Treatment Outcome | 2002 |
[Treatment of Parkinson's disease: use of piribedil].
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Dise | 2004 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergo | 2005 |
Dopamine and depression: a review of recent evidence. I. Empirical studies.
Topics: Amphetamine; Antipsychotic Agents; Brain; Bromocriptine; Depressive Disorder; Dihydroxyphenylalanine | 1983 |
[New directions in contemporary pharmacotherapy of parkinsonism (review)].
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antiparkinson Agents; Apomorphine; Aromatic Amino | 1984 |
Dopamine autoreceptor stimulation: clinical significance.
Topics: Apomorphine; Dopamine; Haloperidol; Humans; Huntington Disease; Mental Disorders; Neurons; Parkinson | 1982 |
Current status of dopamine agonists in Parkinson's disease management.
Topics: Apomorphine; Biological Availability; Dopamine Agents; Ergot Alkaloids; Half-Life; Humans; Parkinson | 1993 |
[Parkinson disease: diagnostic and therapeutic criteria].
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Diagnosis, | 2001 |
[Considerations in the drug treatment of parkinsonism (author's transl)].
Topics: Amantadine; Apomorphine; Bromocriptine; Dopamine; Ergolines; Extrapyramidal Tracts; Female; Humans; | 1978 |
Bromocriptine in the treatment of parkinsonism.
Topics: Apomorphine; Bromocriptine; Catecholamines; Drug Interactions; Ergolines; Humans; Kinetics; Motor Ac | 1979 |
[Cerebral dopaminergic mechanisms. Present status of the problem].
Topics: Depression; Dopamine; Dopamine Antagonists; Humans; Parkinson Disease; Piperazines; Piribedil; Recep | 1979 |
Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
Topics: Apomorphine; Bromocriptine; Humans; Levodopa; Parkinson Disease; Piribedil; Receptors, Dopamine | 1979 |
Progress in understanding and treating Parkinson's disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Enzyme Inhibitors; Ergot Alkaloids; Humans; Levodopa; | 1976 |
Parkinson's disease: pathological mechanisms and actions of piribedil.
Topics: Aged; Aged, 80 and over; Animals; Brain Chemistry; Callithrix; Domperidone; Humans; Iron; Middle Age | 1992 |
32 trials available for piribedil and Parkinson Disease
| Article | Year |
|---|---|
Association of Multiple Dopamine D3 Receptor Gene 3'UTR Polymorphisms with Susceptibility to Parkinson's Disease and Clinical Efficacy of Piribedil Therapy.
Topics: 3' Untranslated Regions; Aged; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; | 2021 |
Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
Topics: Aged; Antiparkinson Agents; Apathy; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Mi | 2013 |
Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Topics: Benserazide; Data Interpretation, Statistical; Drug Combinations; Drugs, Chinese Herbal; Humans; Lev | 2013 |
Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Benserazide; Benzothiazoles; Catechols; Dose-Response Relationship, Drug | 2015 |
Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.
Topics: Administration, Sublingual; Antiparkinson Agents; Apomorphine; Cross-Over Studies; Dose-Response Rel | 2010 |
Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Bromocriptine; Cross-Over Studies; Female; Halluci | 2003 |
Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admin | 2003 |
[The use of pronoran (piribedil) in Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Female; Humans; Male; Middle Aged; Parkinson Disease; Piribedil; Severit | 2003 |
Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience.
Topics: Adult; Aged; Asian People; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; P | 2003 |
[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
Topics: Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodop | 2003 |
[Clinical and stabilometric analysis of postural instability in Parkinson's disease].
Topics: Adult; Aged; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Piribedil; Pos | 2004 |
End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
Topics: Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Infusion | 2005 |
Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; D | 2004 |
[An impact of pronoran on cognitive and affective disorders in Parkinson's disease].
Topics: Adult; Affect; Aged; Antiparkinson Agents; Cognition; Cognition Disorders; Female; Humans; Male; Mid | 2005 |
The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Case-Control Studies; Double-Blind Method; Drug Th | 2006 |
The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Case-Control Studies; Double-Blind Method; Drug Th | 2006 |
The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Case-Control Studies; Double-Blind Method; Drug Th | 2006 |
The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Case-Control Studies; Double-Blind Method; Drug Th | 2006 |
The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Case-Control Studies; Double-Blind Method; Drug Th | 2006 |
The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Case-Control Studies; Double-Blind Method; Drug Th | 2006 |
The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Case-Control Studies; Double-Blind Method; Drug Th | 2006 |
The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Case-Control Studies; Double-Blind Method; Drug Th | 2006 |
The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Case-Control Studies; Double-Blind Method; Drug Th | 2006 |
[The role of pronoran in the therapy of late stage of Parkinson's disease].
Topics: Dopamine Agonists; Drug Administration Schedule; Humans; Parkinson Disease; Piribedil; Receptors, Ad | 2006 |
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fo | 2006 |
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fo | 2006 |
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fo | 2006 |
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fo | 2006 |
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fo | 2006 |
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fo | 2006 |
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fo | 2006 |
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fo | 2006 |
Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fo | 2006 |
[Acute hypotensive effect of a central dopaminergic agonist, piribedil, administered intravenously in the normotensive human].
Topics: Antihypertensive Agents; Body Temperature; Female; Heart Rate; Humans; Injections, Intravenous; Male | 1984 |
A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agent | 1999 |
[Action of piribedil in Parkinson disease. Multicenter study].
Topics: Antiparkinson Agents; Female; Humans; Male; Middle Aged; Parkinson Disease; Piribedil; Severity of I | 1999 |
Studies on piribedil in Parkinsonism.
Topics: Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Humans; Huntington Disease; Mental Disorders | 1975 |
Caffeine and the antiparkinsonian response to levodopa or piribedil.
Topics: Adult; Aged; Caffeine; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Female; | 1975 |
A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism.
Topics: Chronic Disease; Clinical Trials as Topic; Fluphenazine; Humans; Parkinson Disease; Parkinson Diseas | 1977 |
[Long-term clinical and electrophysiological study of a new dopaminergic agonist in 54 patients with parkinsonism].
Topics: Aged; Clinical Trials as Topic; Drug Evaluation; Electrophysiology; Humans; Levodopa; Male; Middle A | 1977 |
Clonidine and the anti-parkinsonian response to L-DOPA or piribedil.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Clonidine; Female; Humans; Levodopa; Male; Middle Aged; P | 1976 |
Actions of dopaminergic agonists in parkinsonism.
Topics: Adult; Aged; Apomorphine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Fema | 1975 |
Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Levodopa; Male; | 1975 |
Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
Topics: Aged; Brain; Clinical Trials as Topic; Dopamine; Drug Evaluation; Drug Therapy, Combination; Female; | 1975 |
Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
Topics: Administration, Oral; Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Inject | 1975 |
Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
Topics: Aged; Amantadine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Huma | 1975 |
[Polygraphic recording of tremor and of hypertonic phenomena. Application to the action of various drugs].
Topics: Antiparkinson Agents; Apomorphine; Clinical Trials as Topic; Dopa Decarboxylase; Drug Combinations; | 1975 |
Activity and acceptability of piribedil in Parkinson's disease: a multicentre study.
Topics: Adult; Aged; Depression; Female; Humans; Male; Middle Aged; Parkinson Disease; Piribedil; Treatment | 1992 |
36 other studies available for piribedil and Parkinson Disease
| Article | Year |
|---|---|
Design and evaluation of thermo-responsive nasal in situ gelling system dispersed with piribedil loaded lecithin-chitosan hybrid nanoparticles for improved brain availability.
Topics: Administration, Intranasal; Biological Availability; Biological Transport; Brain; Chitosan; Drug Com | 2021 |
[Upper gastrointestinal tract dysfunction and its correction by dopamine agonists for patients with Parkinson's disease of I-III stage].
Topics: Adult; Aged; Aged, 80 and over; Deglutition Disorders; Dopamine Agonists; Female; Gastrointestinal D | 2022 |
[Upper gastrointestinal tract dysfunction and its correction by dopamine agonists for patients with Parkinson's disease of I-III stage].
Topics: Adult; Aged; Aged, 80 and over; Deglutition Disorders; Dopamine Agonists; Female; Gastrointestinal D | 2022 |
[Upper gastrointestinal tract dysfunction and its correction by dopamine agonists for patients with Parkinson's disease of I-III stage].
Topics: Adult; Aged; Aged, 80 and over; Deglutition Disorders; Dopamine Agonists; Female; Gastrointestinal D | 2022 |
[Upper gastrointestinal tract dysfunction and its correction by dopamine agonists for patients with Parkinson's disease of I-III stage].
Topics: Adult; Aged; Aged, 80 and over; Deglutition Disorders; Dopamine Agonists; Female; Gastrointestinal D | 2022 |
[Motor and autonomic disorders influence on pain syndrome of patients with Parkinson's disease of the I-III H&Y stages].
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Dopamine Agonists; Female; Humans | 2023 |
Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson's disease.
Topics: Administration, Intranasal; Animals; Biological Availability; Drug Carriers; Drug Delivery Systems; | 2021 |
Optimization of piribedil mucoadhesive tablets for efficient therapy of Parkinson's disease: physical characterization and ex vivo drug permeation through buccal mucosa.
Topics: Acrylic Resins; Adhesiveness; Administration, Buccal; Animals; Calorimetry, Differential Scanning; C | 2017 |
Piribedil: sleep attacks, also in patients without Parkinson's disease.
Topics: Aged; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Piribedil; Sleep Wake | 2013 |
Piribedil and pathological gambling in six parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Female; Gambling; Humans; Male; Middle Aged; Parkinso | 2015 |
[The use of piribedil in early and late stages of Parkinson's disease].
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle | 2015 |
Delusional infestation induced by piribedil add-on in Parkinson's disease.
Topics: Antiparkinson Agents; Delusions; Drug Therapy, Combination; Ectoparasitic Infestations; Female; Hall | 2010 |
Myometry revealed medication-induced decrease in resting skeletal muscle stiffness in Parkinson's disease patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Body Mass Index; Electromyography; Female; Humans; In | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; An | 2013 |
Piribedil-induced sleep attacks in Parkinson's disease.
Topics: Antiparkinson Agents; Disorders of Excessive Somnolence; Dopamine Agonists; Dose-Response Relationsh | 2003 |
[Modern aproaches to the treatment of early stages of Parkinson disease].
Topics: Adult; Aged; Amantadine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Mal | 2005 |
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention Deficit Disorder with Hyperactivity; Cognition; Corpus Stri | 2006 |
Peripheral edema and dopamine agonists in Parkinson disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Edema; Extremities; Humans; Parkinson Disease; Piribedil | 2007 |
Dopamine agonists and Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Brain; Bromocriptine; Ergolines; Ergot Alkaloids; Humans; Levodop | 1984 |
[Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
Topics: Antipsychotic Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Electromyography; Humans; Levo | 1981 |
Piribedil: behavioural, neurochemical and clinical profile of a dopamine agonist.
Topics: Aggression; Animals; Behavior, Animal; Brain; Corpus Striatum; Humans; Motor Activity; Neural Inhibi | 1983 |
The phonological loop in medicated patients with Parkinson's disease: presence of phonological similarity and word length effects.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Female; Frontal Lobe; Humans; Language Tests; Levodop | 1997 |
Sleep attacks and Parkinson's disease treatment.
Topics: Accidents, Traffic; Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Female; Humans; Li | 2000 |
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; | 1976 |
[Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
Topics: Administration, Oral; Adrenergic Agonists; Aged; Drug Therapy, Combination; Electromyography; Female | 1977 |
Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey.
Topics: Animals; Apomorphine; Corpus Striatum; Evoked Potentials; Globus Pallidus; Haloperidol; Haplorhini; | 1979 |
Actions of dopaminergic agonists on cyclic AMP production in rat brain homogenates.
Topics: Animals; Antiparkinson Agents; Apomorphine; Aporphines; Bucladesine; Corpus Striatum; Cyclic AMP; Do | 1975 |
Piribedil in Parkinson's syndrome: a clinical study.
Topics: Activities of Daily Living; Aged; Alkaline Phosphatase; Brain Diseases; Dose-Response Relationship, | 1975 |
[New therapeutic indications for a dopamine antagonist, Piribedyl].
Topics: Affective Symptoms; Female; Humans; Male; Parkinson Disease; Piperazines; Piribedil; Receptors, Dopa | 1978 |
[Experimental and clinical study on the dopaminergic receptor stimulating agents (author's transl)].
Topics: Adult; Aged; Animals; Bromocriptine; Dopamine; Female; Haplorhini; Humans; Male; Middle Aged; Parkin | 1977 |
Brain dopamine turnover and the relief of parkinsonism.
Topics: Brain; Bromocriptine; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson Disea | 1977 |
Brain dopamine turnover and the relief of parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Homovanillic Acid; Humans; Hydroxyindol | 1977 |
Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Topics: Aged; Amantadine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Methyld | 1976 |
Dopaminergic mechanisms in patients with extrapyramidal disease.
Topics: Animals; Biogenic Amines; Brain; Caffeine; Clonidine; Dopamine; Drug Evaluation; Drug Therapy, Combi | 1975 |
Cardiac beta-adrenoceptor sensitivity and Parkinson's disease.
Topics: Aged; Aging; Blood Pressure; Bromocriptine; Dose-Response Relationship, Drug; Female; Heart Rate; Hu | 1991 |
Piribedil therapy in Parkinson's disease. Use of the drug in the retard form.
Topics: Aged; Drug Compounding; Drug Evaluation; Female; Humans; Male; Middle Aged; Parkinson Disease; Piper | 1989 |
[Dopaminergic agonists in Parkinson disease].
Topics: Aged; Bromocriptine; Dopamine; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease; Pergolide; | 1986 |
[Dopamine agonists in the therapy of parkinson syndrome].
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Bromocriptine; Corpus Striatum; Dopamine; Human | 1985 |
Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pip | 1974 |